On July 17, 2025 MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, reported that the first patient has been dosed in its Phase 1 clinical trial to assess the safety and tolerability of MOMA-341, a potent and selective Werner helicase inhibitor with a novel chemical scaffold (Press release, MOMA Therapeutics, JUL 17, 2025, View Source [SID1234654436]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MOMA-341 is being developed as a monotherapy and in combination with chemotherapy or immunotherapy for the treatment of advanced or metastatic solid tumors that exhibit high microsatellite instability (MSI-H) and/or DNA mismatch repair deficiency (dMMR), including colorectal, gastric and endometrial cancers. The fact that Werner helicase is required for survival of MSI-H/dMMR tumor cells makes it a promising emerging drug target. MOMA anticipates an initial readout of monotherapy data in mid-2026.
"We are proud to enter the clinic for the second time in less than a year, with initial readouts for both MOMA-341 and MOMA-313, our novel Polθ helicase inhibitor, expected in early-to- mid 2026," said Asit Parikh, M.D., Ph.D., chief executive officer of MOMA. "Given that MOMA-341’s novel chemical scaffold confers excellent target coverage, we are eager to evaluate its best-in-class potential for patients through this Phase 1 study."
About the MOMA-341 Phase 1 Trial
The Phase 1 clinical trial is a global multi-center, open-label dose escalation and dose optimization study (NCT06974110) designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical activity of MOMA-341 as an orally administered single agent or combination therapy with either the chemotherapy agent irinotecan or immunotherapy. Adult participants must have unresectable advanced or metastatic microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.
About the KNOMATIC platform
MOMA-341 and MOMA-313, were discovered and developed through the application of MOMA’s KNOMATIC platform. The KNOMATIC platform integrates deep structural insights, advanced hit-finding technologies and computation-enabled lead optimization to accelerate discovery of novel therapeutics targeting families of highly dynamic proteins, such as ATPases and GTPases.